Stiripentol

Stiripentol

Stiripentol is an anticonvulsant agent used with clobazam and valproate as an adjunct to treat refractory generalized tonic-clonic seizures in Dravet syndrome. Stiripentol is an anticonvulsant drug used in the treatment of epilepsy as an adjunct therapy along with Clobazam and Valproic acid. This drug is currently approved in the USA, Canada, and European countries as oral tablets marketed as Diacomit. FDA approval of this drug was granted on August 20, 2018 6, 7. Unrelated to other anticonvulsants, stiripentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates the levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system.

Systematic Name

(1E)-1-(2H-1,3-Benzodioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol

Brand Name(S)

Diacomit

Therapeutic Category

Anti-convulsant

Suitable Formulations

Solid

Approvals

US DMF, EU ASMF

EU-WC

Do You Have A Question? Lets Have A Talk

Sthree chemicals is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2012 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals.